PHARMACOGENOMICS

作品数：75被引量：275H指数：10
导出分析报告
相关领域：医药卫生更多>>
相关作者：陈敏郑铭姜锋高红瑾阳丽梅更多>>
相关机构：福建省立医院武汉大学中山大学南京农业大学更多>>
相关期刊：更多>>
相关基金：国家自然科学基金国家高技术研究发展计划国家重点基础研究发展计划SA-SIBS优秀人才奖励基金更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Genetic factors that predict response and failure of biologic therapy in inflammatory bowel disease
《World Journal of Experimental Medicine》2025年第1期11-23,共13页Milena Peruhova Daniela Stoyanova Dimitrina Georgieva Miteva Meglena Kitanova Milko Bozhidarov Mirchev Tsvetelina Velikova 
Supported by The European Union-Next Generation EU,through the National Recovery and Resilience Plan of the Republic of Bulgaria,No.BG-RRP-2.004-0008。
Inflammatory bowel disease(IBD)represents a significant disease burden marked by chronic inflammation and complications that adversely affect patients’quality of life.Effective diagnostic strategies involve clinical ...
关键词：Inflammatory bowel disease Genetic predictors Inflammatory bowel disease treatment Biologic therapy Biologic therapy response Genetic markers in inflammatory bowel disease Inflammatory bowel disease treatment failure PHARMACOGENOMICS Biologic therapy efficacy Genetic variability 
Population-scale variability of the human UDP-glycosyltransferase gene family
《Journal of Genetics and Genomics》2024年第11期1228-1236,共9页Daianna González-Padilla Mahamadou D.Camara Volker M.Lauschke Yitian Zhou 
support from the Swedish Research Council(grant numbers 2021-02801 and 2023-03015);Cancerfonden(grant23-0763 PT);by the SciLifeLab and Wallenberg National Program for Data-Driven Life Science(grant WASPDDLS22:006);the Robert Bosch Foundation,Stuttgart,Germany and from the National Autonomous University of Mexico(UNAM)DGECI program Initiation to Research 2023;supported in part by the South African Medical Research Council(SAMRC)。
Human UDP-glycosyltransferases(UGTs)are responsible for the glycosylation of a wide variety of endogenous substrates and commonly prescribed drugs.Different genetic polymorphisms in UGT genes are implicated in interin...
关键词：UDP-Glycosyltransferases Genetic variants POPULATIONS Drug response Cancer risk PHARMACOGENOMICS 
Research trends in pharmacogenomics of immune diseases:A bibliometric study
《Clinical Research Communications》2024年第3期13-22,共10页Xue-Ting Mao Hong-Ting Nie Guan-Ru Chen Xiao-Ling Wang Xiao-Lin Xu 
the National Key Research and Development Program of China(2021YFC2702005);Beijing Hospitals Authority’s Ascent Plan(DFL20221001);R&D Program of Beijing Municipal Education Commission(KZ202210025030);Beijing Municipal Hospital Scientific Research and Cultivation Program(PX2023043).
Background:Numerous academic studies have explored the utilization of pharmacogenomics in the context of immunologic diseases in recent years.Despite this,there is a notable absence of scientometric analyses focusing ...
关键词：PHARMACOGENOMICS IMMUNIZATION American Science Citation Index Online Edition bibliometrics analysis CITESPACE 
Hydroxychloroquine in SARS-CoV-2 infection:Understanding the misadventure
《Journal of Acute Disease》2024年第2期45-52,共8页David Banji Otilia J F Banji 
The widespread outbreak of SARS-CoV-2 was declared a public health emergency by the World Health Organization and various governments worldwide.This prompted the implementation of stringent infection control measures ...
关键词：SARS-CoV-2 HYDROXYCHLOROQUINE PHARMACOGENOMICS TLR signaling CARDIOTOXICITY 
Effectiveness of pharmacogenomics on the response and remission of treatment-resistant depression: a metaanalysis of randomised controlled trials
《General Psychiatry》2023年第6期443-453,共11页Yu Cheng Hongmei Liu Ruixue Yuan Kai Yuan Shunying Yu 
supported by the 2021 Annual Project of Shanghai Mental Health Center(SMHC)Clinical Research Center(CRC2021ZD02)。
Background Pharmacogenomics(PGx)is a promising tool to realise tailored drug therapy for depression.Aims To investigate the treatment efficacy of PGxfor treatment-resistant depression(TRD)compared with treatmentas usu...
关键词：REMISSION TREATMENT RANDOM 
Pharmacogenetics and pharmacogenomics in glaucoma therapeutics:the way to personalized therapy
《Chinese Medical Journal》2023年第21期2573-2575,共3页Shiyu Liao Lixiang Wang Xin Wei 
supported by grants from the Natural Science Foundation of China(No.82070954);the Innovative Spark Grant of Sichuan University(No.2018SCUH0062);1·3·5 project for disciplines of excellence–Clinical Research Incubation Project,West China Hospital,Sichuan University(No.2021HXFH057);the“0-1’”Innovation Research Project of Sichuan University(No.2022SCUH0036).
Glaucoma is a leading cause of irreversible optic nerve damage,with a significant proportion of patients(approximately 10%)suffering from blindness or severe visual field damage during their lifetime.^([1])The number ...
关键词：GLAUCOMA protective DAMAGE 
Pharmacogenomics-based individualized treatment of hypertension in preterm infants: A case report and review of the literature
《World Journal of Clinical Cases》2023年第30期7440-7449,共10页Lian-Fang Tang Ao Xu Kai Liu 
BACKGROUND Neonatal hypertension is a rare but potentially serious condition that requires careful monitoring and treatment.Pharmacogenomics can help guide individualized drug therapy and improve outcomes.CASE SUMMARY...
关键词：PHARMACOGENOMICS HYPERTENSION PRETERM INFANTS Case report 
Personalized medicine approach to osteoporosis management in women: integrating genetics, pharmacogenomics, and precision treatments
《Clinical Research Communications》2023年第3期22-29,共8页Seyi Samson Enitan Esther Ngozi Adejumo John Osaigbovoh Imaralu Ayodele Ademola Adelakun Oluwakemi Anike Ladipo Comfort Bosede Enitan 
Osteoporosis has emerged as a significant health issue among postmenopausal women.Addressing this concern necessitates a multifaceted approach encompassing genetics,pharmacogenomics,bone turnover markers,lifestyle fac...
关键词：OSTEOPOROSIS MANAGEMENT personalized medicine PHARMACOGENOMICS WOMEN 
Clinical utilities and end-user experience of pharmacogenomics:39 mo of clinical implementation experience in an Australian hospital setting
《World Journal of Medical Genetics》2023年第4期39-50,共12页Rosalind Moxham Andrew Tjokrowidjaja Sophie Devery Renee Smyth Alison McLean Darren M Roberts Kathy H C Wu 
Supported by Partially funded by St Vincent’s Health Australia Inclusive Health Program;Early Career Research Grant from Avant.
BACKGROUND Pharmacogenomics(PG)testing is under-utilised in Australia.Our research provides Australia-specific data on the perspectives of patients who have had PG testing and those of the clinicians involved in their...
关键词：Pharmacogenomics testing Clinical adoption Drug gene interactions Clinician perspectives Patient perspectives 
FOXO3 mutation predicting gefitinib-induced hepatotoxicity in NSCLC patients through regulation of autophagy
《Acta Pharmaceutica Sinica B》2022年第9期3639-3649,共11页Shaoxing Guan Xi Chen Youhao Chen Guohui Wan Qibiao Su Heng Liang Yunpeng Yang Wenfeng Fang Yan Huang Hongyun Zhao Wei Zhuang Shu Liu Fei Wang Wei Feng Xiaoxu Zhang Min Huang Xueding Wang Li Zhang 
supported by the National Natural Science Foundation of China (Grant Nos. 81973398, 81473283, 81730103, 81573507 and 82020108031);The National Key Research and Development Program (Grant Nos. 2017YFC0909300 and 2016YFC0905000, China);Guangdong Provincial Key Laboratory of Construction Foundation (Grant No. 2017B030314030, China);Science and Technology Program of Guangzhou (201607020031, China);National Engineering and Technology Research Center for New drug Druggability Evaluation (Seed Program of Guangdong Province (No. 2017B090903004, China);the 111 project (Grant: B16047, China);China Postdoctoral Science Foundation (Grant Nos. 2019M66324, 2020M683140 and 2020M683139)
Hepatotoxicity is a common side effect for patients treated with gefitinib,but the related pathogenesis is unclear and lacks effective predictor and management strategies.A multi-omics approach integrating pharmacomet...
关键词：GEFITINIB HEPATOTOXICITY Pharmacometabolomic PHARMACOKINETICS PHARMACOGENOMICS FOXO3 AUTOPHAGY 
全选清除导出
共8页<12345678>
检索报告 对象比较 聚类工具 使用帮助 返回顶部